Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other financing activities (2016 - 2025)

Historic Other financing activities for Aytu Biopharma (AYTU) over the last 16 years, with Q4 2025 value amounting to $283000.0.

  • Aytu Biopharma's Other financing activities rose 8741.72% to $283000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 million, marking a year-over-year decrease of 7139.92%. This contributed to the annual value of $576000.0 for FY2025, which is 8022.66% down from last year.
  • Per Aytu Biopharma's latest filing, its Other financing activities stood at $283000.0 for Q4 2025, which was up 8741.72% from $114000.0 recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Other financing activities registered a high of $5.0 million during Q2 2023, and its lowest value of -$856000.0 during Q2 2021.
  • Its 5-year average for Other financing activities is $1.3 million, with a median of $916000.0 in 2023.
  • Per our database at Business Quant, Aytu Biopharma's Other financing activities plummeted by 79270.23% in 2021 and then surged by 62172.9% in 2022.
  • Aytu Biopharma's Other financing activities (Quarter) stood at $1.2 million in 2021, then soared by 149.55% to $3.1 million in 2022, then plummeted by 73.26% to $820000.0 in 2023, then crashed by 81.59% to $151000.0 in 2024, then soared by 87.42% to $283000.0 in 2025.
  • Its Other financing activities was $283000.0 in Q4 2025, compared to $114000.0 in Q3 2025 and $576000.0 in Q2 2025.